Ironwood Pharmaceuticals Inc (IRWD)
6.30
+0.24
(+3.96%)
USD |
NASDAQ |
May 31, 16:00
6.31
+0.01
(+0.16%)
After-Hours: 20:00
Ironwood Pharmaceuticals Research and Development Expense (Annual): 116.08M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 116.08M |
| December 31, 2022 | 44.26M |
| December 31, 2021 | 70.40M |
| December 31, 2020 | 88.06M |
| December 31, 2019 | 115.04M |
| December 31, 2018 | 101.06M |
| December 31, 2017 | 88.14M |
| December 31, 2016 | 139.49M |
| December 31, 2015 | 108.75M |
| Date | Value |
|---|---|
| December 31, 2014 | 101.89M |
| December 31, 2013 | 102.38M |
| December 31, 2012 | 113.47M |
| December 31, 2011 | 86.09M |
| December 31, 2010 | 77.45M |
| December 31, 2009 | 76.10M |
| December 31, 2008 | 59.81M |
| December 31, 2007 | 57.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
44.26M
Minimum
2022
116.08M
Maximum
2023
86.77M
Average
88.06M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Amicus Therapeutics Inc | 152.38M |
| Insmed Inc | 571.01M |
| Altimmune Inc | 65.80M |
| Cassava Sciences Inc | 89.42M |
| InfuSystems Holdings Inc | -- |